Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) LIMD1 Antibodies:
anti-Human LIMD1 Antibodies:
anti-Mouse (Murine) LIMD1 Antibodies:
Go to our pre-filtered search.
These results suggested that LIMD1 is a novel BRCA2-interacting protein and is involved in the centrosome localization of BRCA2 (show BRCA2 Antibodies) and suppression of LIMD1, causing abnormal cell division in EC cells.
Thus, the LIMD1-MYBL1 (show MYBL1 Antibodies) Index had considerable clinical value for DLBCL subtype classification and prognosis.
Cyclic stretch is associated with a JNK (show MAPK8 Antibodies)-dependent increase in binding of a LATS (show LATS1 Antibodies) inhibitor, LIMD1, to the LATS1 (show LATS1 Antibodies) kinase and that reduction of LIMD1 expression suppresses the activation of YAP (show YAP1 Antibodies) by cyclic stretch.
LIMD1 prevents retinoblastoma phosphorylation and downregulates of E2F1 (show E2F1 Antibodies) protein and blocks entry of cells into S-phase.
Data show that the tumour suppressor protein LIMD1 acts as a molecular scaffold, simultaneously binding the PHDs and VHL (show VHL Antibodies), thereby assembling a PHD (show PDC Antibodies)-LIMD1-VHL (show VHL Antibodies) protein complex and creating an enzymatic niche that enables efficient degradation of HIF-1alpha (show HIF1A Antibodies).
PU.1 is a major transcriptional activator of LIMD1
LIMD1 inactivation as primary event than inactivation of RB1 (show RB1 Antibodies) in head and neck squamous cell carcinoma development.
LIMD1 is a tumor-suppressor gene, the protein product of which functionally interacts with pRB (show RB1 Antibodies) and the loss of which promotes lung carcinogenesis
These results suggest that some breast tumors have altered expression of LIMD1 RNA and that LIMD1 may be involved in cell anchoring via focal adhesions and in the cell cycle, particularly during mitosis.
study demonstrates that LIMD1 represents a novel prognostic marker for breast cancer. Combined with the fact that LIMD1 expression is downregulated in lung cancers this clearly indicates that LIMD1 may represent a critical tumor suppressor gene
Limd1 regulates AP-1 (show JUN Antibodies) activation through an interaction with Traf6 (show TRAF6 Antibodies) to influence osteoclast development
Limd1 influences not only stress osteoclastogenesis but also osteoblast function and osteoblast progenitor commitment. Together, these data identify Limd1 as a novel regulator of both bone osetoclast and bone osteoblast development and function.
Adapter or scaffold protein which participates in the assembly of numerous protein complexes and is involved in several cellular processes such as cell fate determination, cytoskeletal organization, repression of gene transcription, cell-cell adhesion, cell differentiation, proliferation and migration. Positively regulates microRNA (miRNA)-mediated gene silencing and is essential for P-body formation and integrity. Acts as a hypoxic regulator by bridging an association between the prolyl hydroxylases and VHL enabling efficient degradation of HIF1A. Acts as a transcriptional corepressor for SNAI1- and SNAI2/SLUG- dependent repression of E-cadherin transcription. Negatively regulates the Hippo signaling pathway and antagonizes phosphorylation of YAP1. Inhibits E2F-mediated transcription, and suppresses the expression of the majority of genes with E2F1- responsive elements. Regulates osteoblast development, function, differentiation and stress osteoclastogenesis. Enhances the ability of TRAF6 to activate adapter protein complex 1 (AP-1) and negatively regulates the canonical Wnt receptor signaling pathway in osteoblasts. May act as a tumor suppressor by inhibiting cell proliferation (By similarity).
LIM domain-containing protein 1
, LIM and cysteine-rich domains protein 1
, LIM domains-containing protein 1